Aura Biosciences, Inc.

NASDAQ:AURA

Biotechnology

Healthcare
$7.14 -1.43%

-$0.09 today

Market cap
$743.09M
Beta
0.39
P/E (TTM)
-3.7
EPS (TTM)
-$1.67
52W Low $4.73High $9.54

Volume 0.69M

Average 0.52M

AURA Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Aura Biosciences, Inc.NASDAQ: AURA

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense dips below year-ago levels

Q1 FY2026 income tax expense of $11K fell 38.9% year over year, behind the +17.6% change in trailing-twelve-month income tax expense. Sequentially, it fell 26.7% from the prior quarter.

Context

  • Income tax expense increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -38.9% toward the trailing-twelve-month pace of +17.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$11K-26.7% QoQ
Last fiscal yearDec 2025
$108K-3.6% YoY
LTMMar 2026
$100K+17.6% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-38.9%——
1 year-3.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
108K USD
Year-over-year change
-3.6%

Income Tax Expense vs competitors

How AURA compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +17.6% is the 2nd highest of 6, against a peer median of -147.8%.
AURA Competitors
Income Tax Expense for AURA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BCYCBicycle Therapeutics plcLTM Mar 2026$1.41M USD+125.6%—2.2%
AURAAura Biosciences, Inc.LTM Mar 2026$100K USD+17.6%——
IMNMImmunome, Inc.LTM Sep 2026$0 USD———
AKTSAktis Oncology, Inc.FY2025$0 USD——0.0%
OCGNOcugen, Inc.LTM Mar 2026$0 USD——0.0%
WHWKWhitehawk Therapeutics IncLTM Mar 2026$0 USD———
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$0 USD———
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026-$43K USD-147.8%—0.6%
OCSOculis Holding AGLTM Mar 2026-CHF 291.8K CHF-59.5%+47.8%57.9%
MGNXMacroGenics, Inc.LTM Mar 2026-$672K USD-171.2%—0.4%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$1.55M USD-55622.5%—466.7%
Peer median (excluding AURA) —-147.8%+47.8%0.6%

Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue001.3M00
Gross Profit00(1.3M)00
Gross Margin—————
Research & Development25.16M42.24M63.94M73.3M90.3M
Selling, General & Admin10.09M18.06M19.76M22.81M22.49M
Operating Expenses35.25M60.3M83.7M96.12M112.79M
Depreciation & Amortization831K1.18M1.3M1.22M1.13M
EBITDA(34.41M)(57.59M)(74.98M)(85.58M)(104.95M)
EBITDA Margin—————
Operating Income(35.25M)(60.3M)(84.99M)(96.12M)(112.79M)
Operating Margin—————
Interest Income13K1.86M8.59M9.43M6.63M
Interest Expense13K0000
Other Income / Expenses(1K)1.53M8.72M9.31M6.71M
Income Before Tax(35.25M)(58.76M)(76.27M)(86.81M)(106.08M)
Pre-Tax Margin—————
Income Tax Expense00137K112K108K
Net Income(35.25M)(58.76M)(76.41M)(86.92M)(106.19M)
Net Margin—————
EPS (Basic)(1.58)(1.96)(1.93)(1.75)(1.76)
EPS (Diluted)(1.58)(1.96)(1.93)(1.75)(1.76)
Weighted Avg Shares29.21M29.94M39.62M49.65M60.34M
Weighted Avg Shares (Diluted)29.21M29.94M39.62M49.65M60.34M

Aura Biosciences, Inc.

NASDAQ:AURA

Intrinsic Alpha fair value

Locked

Current Price

$7.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.